<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476409</url>
  </required_header>
  <id_info>
    <org_study_id>15-0472</org_study_id>
    <nct_id>NCT02476409</nct_id>
  </id_info>
  <brief_title>Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders</brief_title>
  <acronym>TROUPER</acronym>
  <official_title>Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who present to clinic or in the outpatient setting with worsening heart failure&#xD;
      represent a unique opportunity for novel approaches to decongestion (removing fluid) that may&#xD;
      more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization.&#xD;
&#xD;
      In these patients with less severe congestion (fluid overload), combining the vasopressin&#xD;
      antagonist tolvaptan with loop diuretics (or fluid pills like&#xD;
      furosemide/bumetanide/torsemide) may represent a more effective strategy for decongestion. In&#xD;
      addition, looking at patients' copeptin levels may help identify those who are more likely to&#xD;
      respond to tolvaptan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, double blind, positive control, multi-center clinical trial&#xD;
      enrolling patients who present in the outpatient setting with signs and symptoms consistent&#xD;
      with worsening congestive heart failure. The sample size for the study is 40 patients.&#xD;
      Candidates for the study will be identified by screening outpatients presenting with&#xD;
      worsening heart failure.&#xD;
&#xD;
      Patients who qualify for the study will be enrolled within 24 hours of identification.&#xD;
      Patients will be randomized in a 1:1 fashion to one of two treatment arms:&#xD;
&#xD;
        -  Augmentation of current daily dose of oral loop diuretic + 30 mg of oral Tolvaptan daily&#xD;
&#xD;
        -  Augmentation of current daily dose of oral loop diuretic + placebo of oral Tolvaptan&#xD;
           daily&#xD;
&#xD;
      Patients will initiate study medication in a hospital setting and will be observed for a&#xD;
      period of time that will depend upon their baseline serum sodium and response to study drug.&#xD;
      In most cases patients will be observed for 8 hours. Following this observational period,&#xD;
      patients will leave the hospital setting and the remainder of the study will consist of&#xD;
      follow-up by outpatient visits or by telephone. All patients will have Day 30 follow up phone&#xD;
      contact for assessment of vital status, adverse events and morbidity during this period.&#xD;
&#xD;
      The primary objectives of this study will be to compare the effects of oral tolvaptan plus&#xD;
      augmented loop diuretic versus augmented loop diuretic on 1) short term changes in body&#xD;
      weight with and without stratification for baseline copeptin and 2) an index targeted to&#xD;
      signs and symptoms of congestion in patients presenting with worsening congestive heart&#xD;
      failure in the outpatient setting with and without prespecified post hoc stratification based&#xD;
      on baseline copeptin level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The primary endpoint for the study will be change in body weight between patients randomized to tolvaptan versus placebo from baseline to 48 hours with and without stratification for baseline copeptin level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in congestion (patient reported and investigator assessed)</measure>
    <time_frame>48 hours and day 8</time_frame>
    <description>Changes in the patient reported and investigator assessed congestion index based on the Likert scale from baseline to 48 hours. Changes in the patient reported and investigator assessed index of congestion at 8 days based on the Likert scale.&#xD;
Changes in the patient reported and investigator assessed index of congestion from baseline to 48 hours and 8 days based on the visual analog scale .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight at day 8</measure>
    <time_frame>8 days</time_frame>
    <description>Change in body weight at 8 days will be analyzed in a similar fashion to the change in body weight at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical composite of morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>This composite will include days of hospitalization, Emergency Department (ED) visits, clinic visits not required by the protocol during the 30 days after randomization into the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory endpoint longitudinal changes in renal function</measure>
    <time_frame>48 hours and day 8</time_frame>
    <description>Longitudinal changes in renal function</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory endpoint longitudinal changes in serum sodium</measure>
    <time_frame>48 hours and day 8</time_frame>
    <description>Longitudinal changes in serum sodium</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory endpoint longitudinal changes in copeptin</measure>
    <time_frame>48 hours and day 8</time_frame>
    <description>Longitudinal changes in copeptin</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Augmentation of current dose of loop diuretic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolvaptan</intervention_name>
    <description>Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for tolvaptan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years of age&#xD;
&#xD;
          -  Presenting to clinic with worsening heart failure due congestion (fluid overload)&#xD;
             Patient reported worsening fluid overload based on perception of edema and/or weight&#xD;
             gain With at least one of the following symptoms&#xD;
&#xD;
               -  Worsening dyspnea on exertion or fatigue&#xD;
&#xD;
               -  Worsening orthopnea or paroxysmal nocturnal dyspnea (PND)&#xD;
&#xD;
               -  Perception of abdominal and/or lower extremity edema&#xD;
&#xD;
               -  Early satiety and/or decreased appetite And at least one of the following signs&#xD;
&#xD;
               -  Lower extremity edema&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Elevated jugular venous distension (JVD)&#xD;
&#xD;
               -  Pulmonary rales&#xD;
&#xD;
          -  Daily oral dose of loop diuretic&#xD;
&#xD;
          -  Prior history of heart failure with this diagnosis for at least 1 month with preserved&#xD;
             or reduced left ventricular ejection fraction&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic hyponatremia will be excluded from the study.&#xD;
&#xD;
          -  Patients with severe hyponatremia, defined as serum sodium &lt; 125 milliequivalents per&#xD;
             Liter (mEq/L) at the time of screening, will be excluded regardless of whether they&#xD;
             are symptomatic or not.&#xD;
&#xD;
          -  Patients with the following predisposing factors for osmotic demyelinating syndrome&#xD;
             (ODS), assessed by the study investigator judgment, will be excluded: chronic&#xD;
             alcoholism at the time of study, severe liver disease, marked malnutrition, and risk&#xD;
             for chronic hypoxia.&#xD;
&#xD;
          -  Patients currently undergoing renal replacement therapy&#xD;
&#xD;
          -  Planned hospitalization for acute heart failure&#xD;
&#xD;
          -  History of primary significant liver disease or acute hepatic failure, as defined by&#xD;
             the investigator&#xD;
&#xD;
          -  Hemodynamically significant arrhythmias&#xD;
&#xD;
          -  Acute coronary syndrome (ACS) or acute myocardial infarction within 4 weeks prior to&#xD;
             study entry&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Hypertrophic obstructive, restrictive, or constrictive cardiomyopathy&#xD;
&#xD;
          -  Severe stenotic valvular disease amendable to surgical treatment&#xD;
&#xD;
          -  Complex congenital heart disease&#xD;
&#xD;
          -  Constrictive pericarditis&#xD;
&#xD;
          -  Clinical evidence of digoxin toxicity&#xD;
&#xD;
          -  History of adverse reaction or clinical contraindication to tolvaptan&#xD;
&#xD;
               -  Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors&#xD;
&#xD;
               -  Inability of patient to sense and/or respond to thirst&#xD;
&#xD;
               -  History of hypersensitivity to tolvaptan&#xD;
&#xD;
               -  Patient is anuric&#xD;
&#xD;
          -  Enrollment or planned enrollment in another randomized clinical trial during the study&#xD;
             period&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Inability to comply with planned study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirkwood F Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004 Apr 28;291(16):1963-71.</citation>
    <PMID>15113814</PMID>
  </reference>
  <reference>
    <citation>Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.</citation>
    <PMID>17384438</PMID>
  </reference>
  <reference>
    <citation>Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009 Sep;30(18):2233-40. doi: 10.1093/eurheartj/ehp253. Epub 2009 Jun 27.</citation>
    <PMID>19561338</PMID>
  </reference>
  <reference>
    <citation>Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.</citation>
    <PMID>17384437</PMID>
  </reference>
  <reference>
    <citation>Morgenthaler NG, Struck J, Jochberger S, DÃ¼nser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008 Mar;19(2):43-9. doi: 10.1016/j.tem.2007.11.001.</citation>
    <PMID>18291667</PMID>
  </reference>
  <reference>
    <citation>Szinnai G, Morgenthaler NG, Berneis K, Struck J, MÃ¼ller B, Keller U, Christ-Crain M. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007 Oct;92(10):3973-8. Epub 2007 Jul 17.</citation>
    <PMID>17635944</PMID>
  </reference>
  <reference>
    <citation>Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006 Jan;52(1):112-9. Epub 2005 Nov 3.</citation>
    <PMID>16269513</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>congestive heart failure</keyword>
  <keyword>tolvaptan</keyword>
  <keyword>copeptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

